ARGX vs TMDX
argenx SE vs TransMedics Group, Inc. — AI-powered side-by-side comparison
VS
TMDX
TransMedics Group, Inc.
60
Buy
| Metric | ARGX | TMDX |
|---|
| AI Score |
69
|
60
|
| Price |
$864.40
|
$89.39
|
| P/E Ratio |
31.34×
|
20.22×
|
| ROE |
17.6%
|
40.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
58.7%
|
| Debt / Equity |
0.01×
|
1.68×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
76.9
|
| Beta |
-0.022
|
1.88
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus TMDX.
ARGX leads by 9 points.
ARGX scores 69/100 (Buy) versus TMDX at 60/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TMDX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 25.8% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 26.6% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 33.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 25.8% YoY -- genuine top-line momentum — Growth
- EPS growing 105.5% YoY — Growth
Bear Case
- Price-to-book of 8.8x prices in significant intangible value — Value
- RSI at 77 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical